...using the Mitomic Technology platform it obtained through its 2014 acquisition of Mitomics Inc. Mitton said Mitomics...
...DNA from pseudogenes that also contain small repeating sequences characteristic of mitochondrial DNA. However, because Mitomics...
...said MDNA’s first order of business was to validate the 3.4 kB mitochondrial DNA deletion Mitomics...

...Core Mitomic Test . The test will be performed at Mitomics' CLIA-certified laboratory. Last year, Mitomics...
...a cancerization field effect by detecting large-scale mitochondrial DNA deletions in non-malignant prostate needle biopsies. Mitomics...
...to provide financial details, while LabCorp could not be reached (see BioCentury, April 11, 2011). Mitomics Inc....

...granted LabMD non-exclusive, U.S. commercialization rights to Mitomics' Prostate Core Mitomic Test . Last year, Mitomics...
...biopsies. Terms were not disclosed (see BioCentury, April 11, 2011). LabMD Inc. , Atlanta, Ga. Mitomics Inc....

...QDx received non-exclusive rights from Mitomics to develop and commercialize the mitochondrial marker behind Mitomics' prostate...
...cells. QDx will use the marker to develop its early stage QPredict Prostate Mitomic Test. Mitomics...
...launched PCMT in the U.S. in March. Terms were not disclosed (see BioCentury, April 11). Mitomics Inc....

...determine the presence or absence of cancerous cells and is available through Mitomics' CLIA-certified laboratory. Mitomics Inc....